Abstract
Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.
| Original language | English |
|---|---|
| Journal | Blood Pressure Monitoring |
| Volume | 6 |
| Issue number | SUPPL. 1 |
| State | Published - 2001 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
- Internal Medicine
Cite this
Pharmacoeconomics of combination antihypertensive therapy. / Hilleman, Daniel E.
In: Blood Pressure Monitoring, Vol. 6, No. SUPPL. 1, 2001.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pharmacoeconomics of combination antihypertensive therapy
AU - Hilleman, Daniel E.
PY - 2001
Y1 - 2001
N2 - Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.
AB - Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0035200252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035200252&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:0035200252
VL - 6
JO - Blood Pressure Monitoring
JF - Blood Pressure Monitoring
SN - 1359-5237
IS - SUPPL. 1
ER -